Therapeutic and prophylactic role of cognitive enhancers in electroconvulsive therapy-induced cognitive deficits
- PMID: 33223724
- PMCID: PMC7660005
- DOI: 10.4103/ipj.ipj_105_20
Therapeutic and prophylactic role of cognitive enhancers in electroconvulsive therapy-induced cognitive deficits
Abstract
Objectives: The objective is to evaluate the pattern of cognitive deficits after electroconvulsive therapy (ECT); to ascertain the role of various psychosocial, illness and treatment-related parameters on cognitive functions after ECT; and to evaluate the effect of donepezil on various cognitive deficits.
Materials and methods: A triple-blind randomized controlled trial was undertaken. Ninety patients undergoing ECT were included into study after due consent and institutional ethical approval. They were randomized into two groups: one using donepezil with ECT and the other using placebo with ECT. Various cognitive parameters were studied before ECT, after a course of ECT and after 4 weeks of last ECT. Findings were assessed in the light of available socialdemographic and clinical parameters and existing literature.
Results: ECT was found to be an effective therapeutic modality. Immediate memory worsened over the course of ECT till after 4 weeks of ECT. Augmentation of donepezil was found useful. It sped up the improvement of general memory and working memory during ECT.
Conclusion: Donepezil has therapeutic and prophylactic benefit on cognition of patients undergoing ECT over the course of treatment till 4 weeks after the ECT.
Keywords: Cognition; donepezil; electroconvulsive therapy; immediate memory.
Copyright: © 2020 Industrial Psychiatry Journal.
Conflict of interest statement
There are no conflicts of interest.
Similar articles
-
Therapeutic and prophylactic utility of the memory-enhancing drug donepezil hydrochloride on cognition of patients undergoing electroconvulsive therapy: a randomized controlled trial.J ECT. 2006 Sep;22(3):163-8. doi: 10.1097/01.yct.0000230365.81368.2d. J ECT. 2006. PMID: 16957530 Clinical Trial.
-
Effect of Donepezil on Cognitive Deficits Associated With Electroconvulsive Therapy: A Randomized Triple-blind Clinical Trial.Clin Neuropharmacol. 2019 Mar/Apr;42(2):27-31. doi: 10.1097/WNF.0000000000000323. Clin Neuropharmacol. 2019. PMID: 30875343 Clinical Trial.
-
Efficacy of donepezil for the attenuation of memory deficits associated with electroconvulsive therapy.Psychiatry Res. 2020 Nov;293:113397. doi: 10.1016/j.psychres.2020.113397. Epub 2020 Aug 18. Psychiatry Res. 2020. PMID: 32835925 Clinical Trial.
-
A Systematic Review on Cognitive Effects of Electroconvulsive Therapy in Asian Patients.Clin Psychopharmacol Neurosci. 2022 Feb 28;20(1):1-16. doi: 10.9758/cpn.2022.20.1.1. Clin Psychopharmacol Neurosci. 2022. PMID: 35078944 Free PMC article. Review.
-
Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies.Health Technol Assess. 2005 Mar;9(9):1-156, iii-iv. doi: 10.3310/hta9090. Health Technol Assess. 2005. PMID: 15774232 Review.
References
-
- Hirshbein L. Historical essay: Electroconvulsive therapy, memory, and self in America. J Hist Neurosci. 2012;21:147–69. - PubMed
-
- Abrams R. The mortality rate with ECT. Convuls Ther. 1997;13:125–7. - PubMed
-
- Semkovska M, McLoughlin DM. Objective cognitive performance associated with electroconvulsive therapy for depression: A systematic review and meta-analysis. Biol Psychiatry. 2010;68:568–77. - PubMed
-
- United States Food and Drug Administration. Executive Summary: Meeting to Discuss the Classification of Electroconvulsive Therapy Devices (ECT) Meeting of the Neurological Devices Panel. 2011
-
- Sharma V. The effect of electroconvulsive therapy on suicide risk in patients with mood disorders. Can J Psychiatry. 2001;46:704–9. - PubMed
LinkOut - more resources
Full Text Sources